Virologic failure was infrequent with both treatment strategies.
Efficacy and tolerability appear comparable to that seen in HCV-monoinfected populations with no significant impact on control of HIV disease.
Sofosbuvir plus ribavirin administered for 12 or 24 weeks depending on HCV genotype and treatment experience was associated with SVR12 rates of 84% to 89% in this coinfected population.
This negative study of an NRTI-sparing strategy in patients with CCR5-tropic virus was closed early by the independent data and safety monitoring committee.
Patients who maintained HIV-1 RNA < 50 copies/mL experienced no increase in virologic failure, whereas even transient increases > 200 copies/mL did increase risk.
The findings were limited by the unknown contribution of adherence, unknown causes for antiretroviral switching, and unknown role of drug resistance in switching and/or subsequent virologic failure.
No cases of virologic failure with dolutegravir in patients receiving NRTI-only background regimens, including among patients receiving NRTIs with reduced susceptibility.
Race, high baseline HIV-1 RNA level, incomplete self-reported adherence, and low levels of genotypic resistance to NRTIs at baseline significantly predicted failure of NRTI-based second-line therapy by 96 weeks
Persons at higher sexual risk were more likely to elect to take and adhere to PrEP
In patients with normal BMI before starting ART, weight gain in the first year of ART was significantly associated with increased risk of cardiovascular disease.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.